ELANOTIC schwannoma is a rare neuroectodermal tumor originating from the Schwann cells of the nerve sheaths, accounting for less than 1% of primary peripheral nerve sheath tumors. It was first described in 1932 by Millar and colleagues, 53 who reported one case involving the thoracic sympathetic ganglion. A melanotic schwannoma is a pathological variant that can be sporadic or part of the Carney complex, a dominantly inherited syndrome characterized by spotty skin pigmentation, endocrine overactivity, and myxomas. 12, 13 The melanotic schwannoma of the Carney complex is a psammomatous melanotic schwannoma; approximately 50% of psammomatous melanotic schwannomas are characterized by the Carney complex. Dumbbell-shaped psammomatous melanotic schwannomas are extremely rare, and in the literature, only one dumbbell-shaped melanotic schwannoma has been reported as located in the dorsal spine and having benign features.
preoperative workup included a CT bone window scan and angiography. The CT scan revealed that the vertebral foramen was enlarged, but its edges were smooth and regular. The vertebral angiography study showed that the VA was slightly lateralized but not compressed. The neurological examination results showed slight muscle weakness in the right arm (Medical Research Council Grade 4) with hyperesthesia in the right occipitocervical region.
The family history of the patient was positive for other malignant stromal tumors. Specifically, the patient's father had undergone an operation to treat a GIST and was currently receiving chemotherapy with imatinib. The patient's sister underwent an operation for a small malignant melanoma in her left shoulder, which did not contain satellite lymph nodes.
Operative Course. A posterior approach to the surgery was planned for the C2-3 hemilaminectomy using radioscopic control. A right-sided dumbbell-shaped intra-extradural mass was found, black in color and smooth in aspect, which had enlarged the vertebral foramen and greatly thickened its edges. The hemilaminectomy procedure was therefore extended with a foraminotomy and complete removal of the lateral peduncles of C2-3 to completely free the extradural mass. The tumor was embedded in the external stromal layer of the VA, so a great deal of work was used to debride the mass itself from the venous plexus of the VA. The midline opening of the dura mater revealed the residual intradural portion, originating from the dorsal root of C-2. Gross-total resection was achieved by sacrificing the C-2 dorsal root. 
Histopathological Analysis and Postoperative Course.
Histopathological examination of the tumor revealed polygonal neoplastic cells with severe nuclear pleomorphism, atypia, and macronucleoli; wide cytoplasm with diffuse melanin granules; and high mitotic activity (5 ϫ 10 hpf). The stroma also included sprinkle cells and psammomatous bodies. Immunohistochemical staining was positive for HMB-45, S100, and tyrosinase, and negative for melanin A. The proliferation index Ki 67 was quite high (12%), and neurofilaments and glial fibrillary acidic protein were positive in the neural fibers. Malignant psammomatous melanotic schwannoma was diagnosed in the patient (Fig. 4) .
The clinical workup was completed with a thorough dermatologic examination, heart ultrasonography, endocrinological evaluation and hormone administration, ocular ultrasonography, and a total-body CT scan, to exclude the Carney complex. The same workup was performed in the patient's immediate relatives. All examinations showed negative results for the Carney complex. The genetic evaluation of the family was negative for mutations of the Carney complex gene (PRKAR1-␣) located on 17q22-24. The postoperative MR image of the cervical spine revealed the complete removal of the lesion, and a complete craniospinal MR imaging study was performed to exclude the presence of drop metastasis.
The postoperative course was uneventful, with complete resolution of the cervical pain and good healing of the surgical wound. The patient used a Philadelphia collar for 1 month. She was encouraged to receive radiotherapy due to the high malignant potential of the lesion, but she refused because of the high risk of radiation-induced lesions. Therefore a clinical radiological follow up was planned, and the craniospinal MR images obtained 3 and 6 months postoperatively did not reveal any relapse or drop metastasis (Fig. 5) . Unfortunately, the craniospinal MR image obtained 12 months after surgery revealed signs of tumor progression into the subarachnoid space at the C-3 level (Fig. 6 ).
Discussion
Psammomatous melanotic schwannomas were first described in 1932 by Millar, 53 who reported a case involving the sympathetic ganglion. In 1961 Hodson 34 reported this rare neurogenic tumor that affected the cranial nerves, alveolar nerves, palate, parotid gland, and neck. Subsequently, in 1985 Carney and colleagues 13 described an autosomal dominant syndrome characterized by a complex of spotty pigmentations of mucosa and skin, myxomas, and endocrine overactivity (particularly Cushing syndrome secondary to adrenocortical pigmented hyperplasia), and thyroid dysfunction, now known as the Carney complex.
Approximately 50% of patients with psammomatous melanotic schwannomas are affected by the Carney complex. The other 50% of psammomatous melanotic schwannomas are sporadic lesions, as are the nonpsammomatous melanotic schwannomas. Melanotic schwannomas are generally derived from spinal nerves and sympathetic ganglia, but extraneural locations have also been described. Intramedullary tumors are quite rare. The typical site of melanotic schwannomas is intraspinal extramedullary, especially in the thoracic region. Most melanocytic schwannomas are located at the vertebral foramen or the paravertebral sulcus.
Different theories exist regarding the histogenesis of this tumor. Schwann cells and melanocytes are both of neuroectodermal origin and melanocytes appear to migrate with Schwann cells. 5 51 Menneymer, 52 and Noubari 58 and their colleagues supported this theory with electron microscopy data, showing that Schwann cells produce melanin.
The biological behavior of melanocytic schwannomas remains unclear, because even lesions considered benign without mitosis, atypia, or necrosis may present with recurrence and/or metastasis, even after many years. In particular, in large literature reviews, Killeen and associates 41 described recurrence and/or metastasis in 24 and 10% of cases, respectively, with the worst prognosis for patients with incompletely excised tumors and tumors located in the cranial nerves; Vallat-Decouvelaere and colleagues 78 reported a 15% rate of recurrence and a 26.3% rate of metastasis for melanotic schwannomas; the lungs were the most common site for metastasis in this study. Vallat-Decouvelaere et al. 78 also concluded that a low mitotic count does not necessarily indicate a benign outcome, after reporting that of five patients with melanotic schwannomas without histopathological features of malignancy, mitosis, or a low mitotic rate, four died from tumor progression.
In patients with melanotic schwannomas, the percentage of malignant tumors is very low at the initial diagnosis, but the risk of possible malignant transformation of a melanotic schwannoma should be always taken into consideration. The follow up of these patients should be rigorous and focused not only on the primitive tumor regrowth but also on the meningeal drop metastasis and the remote locations, especially in the lungs. A recent review 20 on total spinal extramedullary melanotic schwannomas in the literature found 47 cases as of January 2006, but the authors of this review did not focus on malignancy, recurrences, metastasis, or survival rate.
We reviewed all the literature concerning melanotic schwannoma and found 105 cases that were not related to the Carney complex. [1] [2] [3] [4] 54, In particular, we were able to distinguish the primitive nonpsammomatous from the psammomatous melanotic schwannomas to focus on the cases of malignant melanotic schwannoma, indicated by the presence of a high level of mitosis, necrosis, pleomorphism, and nuclear atypia. This review also focused on patient follow up, the malignant progression of the tumor with local recurrences and metastasis, and the survival rate (Table 1) .
We found that 15 of 105 melanocytic schwannomas 8, 15, 18, 30, 35, [40] [41] [42] [43] 47, 63, 78 were psammomatous melanotic schwannomas not related to the Carney complex, and 90 were nonpsammomatous melanotic schwannomas. Seventeen (16.2%) of 105 patients were given a diagnosis of a malignant tumor. 6, 11, 14, 26, 29, 38, 43, 50, 58, 61, 65, 67, 77, 80 One patient presented with drop metastasis in the conus medullaris region, but the histological examination of the tumor revealed only benign features. 75 Unfortunately, long-term follow-up data were available in only 72 of the reported cases, because 33 of the cases reviewed lacked a thorough follow up. Twenty-eight of the 72 patients had a malignant progression of their tumors and received adequate follow up. 8, 9, 16, 19, 38, 41, 44, 45, 47, 50, 52, 58, 62, 65, 66, 75, 78, 80 Specifically, 12 patients had local recurrences, nine had metastasis or leptomeningeal spreading without local recurrence, and seven had both local recurrence and metastasis, resulting in a malignant progression rate of 26.7% compared with the total number of cases (105) with melanotic schwannomas. If only the population with malignant progression and long-term follow up is considered, the malignant progression rate was 38.9%.
We were not able to obtain sufficient data to calculate a survival rate after 12 or 24 months; we can only state that at 12 months, 63 of 105 patients (or 63 of the 72 patients with available follow-up data) were still alive, and among these, 38 were disease free. At 24 months the number of patients still living was 48, 26 of whom were also disease free.
If only the population with psammomatous schwannomas is considered, four of these patients had tumors that progressed to malignancy. 8, 44, 47, 78 One patient with a psammomatous schwannoma, with histopathological findings of malignancy at diagnosis, was disease free 1 year after surgery. 43 Five of the 15 patients with psammomatous schwannomas were disease free for longer than 1 year after surgery; [40] [41] [42] [43] 63 for one of these patients the follow-up period lasted 5 years, and for another 6 years. Five patients did not have any follow up. Therefore, the percentage of malignant progression of psammomatous tumors (26.7%) was identical to the percentage of tumors that underwent malignant progression in the entire group of melanotic schwannomas, suggesting that the characteristic of a psammomatous or nonpsammomatous tumor does not have a prognostic value. The finding of a psammomatous schwannoma is mandatory for the exclusion of the Carney complex.
Thus, considering the biological behavior of this tumor, which can undergo malignant progression and cerebrospinal fluid seeding despite its benign histological features, treatment with complete excision and a strict follow up of the patient is mandatory, particularly in those lesions with malignant features at presentation, such as in the patient in this report. In particular, in this patient's family, the current presence of GIST, malignant melanoma, and malignant psammomatous melanotic schwannoma could indicate a genetic abnormality, different and separate from the Carney complex.
We would like to emphasize that in the literature 75 found, both in melanotic schwannomas and in tumors such as GISTs and malignant melanomas, positivity for the CD117 marker (c-kit). This marker is important for oncology treatments as the target of imatinib, a chemotherapeutic agent already used in chronic myelogenous leukemia as well as in GIST, with excellent results. The mechanism of action of imatinib consists of a competitive inhibition of a tyrosine kinase associated with CD117 and other receptors.
In patients with GIST, such as in the father of the patient in this report, the efficacy of imatinib depends on the levels of expression of CD117. Imatinib is now used in clinical trials for malignant melanoma and the expression of CD117 has recently been reported in malignant melanotic schwannomas. In our patient, the CD117 marker in neoplastic cells was absent. Nevertheless, it could be interesting to investigate if other markers exist in different stromal tumors, especially to be considered as targets for other therapeutic agents.
